Acne Pipeline Yields Three Disappointments, One Win So Far In 2017

The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.

Acne on face

Allergan PLC and Paratek Pharmaceuticals Inc. had the only positive acne data out of four later-stage programs that have reported results so far in 2017 when the partners unveiled Phase III results for sarecycline, a potentially safer cycline oral antibiotic.

Allergan/Paratek, Xenon Pharmaceuticals Inc. and Foamix Pharmaceuticals Ltd. all reported acne clinical trial data in late March, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By 

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By 

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Therapy Areas

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By 

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By 

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.